Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2
The aim of the study was to compare the severity of illness between groups of patients (Facio-Scapulo-Humeral Dystrophy = FHSD1, FSHD2 and patients both FSHD1 and FSHD2).
Despite advances in research on the subject, answers are still needed on these diseases.
We also aim to determine whether the chromosomal genetic abnormality is involved in other diseases and the frequency of this mutation in the population of patients FSHD.
This study will increase our knowledge of the two forms of FSHD who present a common pathophysiological mechanism and may occur together in the same family with a worsening of the clinical phenotype worsening . In addition, epigenetic differences between FSHD type 1 and type 2 seems to have clinical consequences requiring appropriate management
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2|
- Muscle damage measure [ Time Frame: One time at the inclusion ] [ Designated as safety issue: No ]
- Level of muscle damage [ Time Frame: One time at the inclusion ] [ Designated as safety issue: No ]
|Study Start Date:||October 2013|
|Estimated Primary Completion Date:||October 2016 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01970735
|Contact: Sabrina SACCONI, Dr||+33 email@example.com|
|Hôpital Archet 1||Recruiting|
|Nice, France, 06202|
|Contact: Sabrina SACCONI, Dr +33 492039002 firstname.lastname@example.org|
|Principal Investigator: Sabrina SACCONI, Dr|